Quality-adjusted time without symptoms of disease progression or toxicity of treatment (Q-TWiST) analysis to assess benefit-risk of sacituzumab govitecan (SG) in previously treated patients (pts) with metastatic triple-negative breast cancer (mTNBC)

被引：1

作者：

Brufsky, A. M. ^{[1
,2
]}

Bardia, A. ^{[3
]}

Sedrak, M. S. ^{[4
]}

Loibl, S. ^{[5
,6
]}

Tolaney, S. M. ^{[7
]}

Punie, K. ^{[8
,9
,10
]}

Hurvitz, S. A. ^{[11
]}

Kalinsky, K. ^{[12
]}

Cortes, J. ^{[13
]}

O'Shaughnessy, J. ^{[14
]}

Dieras, V. C. ^{[15
]}

Piccart, M. ^{[16
]}

Dasgupta, A. ^{[17
]}

Kaushik, A. G. ^{[17
]}

Lai, C. ^{[18
]}

Shi, L. ^{[19
]}

Rugo, H. S. ^{[20
]}

机构：

[1] Univ Pittsburgh, Med Ctr, Magee Womens Hosp, Dept Hematol Oncol, Pittsburgh, PA USA

[2] Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA USA

[3] UCLA Hlth Jonsson Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA USA

[4] Univ Calif Los Angeles, UCLA Hlth Jonsson Comprehens Canc Ctr, Canc & Aging Program, David Geffen Sch Med,Div Med Oncol, Los Angeles, CA USA

[5] German Breast Grp, Forsch, Neu Isenburg, Germany

[6] Ctr Haematol & Oncol Bethanien, Frankfurt, Germany

[7] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[8] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven Canc Inst, Leuven, Belgium

[9] Univ Hosp Leuven, Multidisciplinary Breast Ctr, Leuven Canc Inst, Leuven, Belgium

[10] Katholieke Univ Leuven, Dept Oncol, Expt Oncol Lab, Leuven, Belgium

[11] Fred Hutchinson Canc Ctr, Div Hematol & Oncol, Dept Med, UW Med,Clin Res Div, Seattle, WA USA

[12] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[13] Quironsalud Grp, Int Breast Canc Ctr, Barcelona, Spain

[14] Baylor Univ, Med Ctr, Texas Oncol, US Oncol, Dallas, TX USA

[15] UNICANCER, Ctr Eugene Marquis, Rennes, France

[16] Univ Libre Bruxelles, Inst Jules Bordet, Brussels, Belgium

[17] Gilead Sci Inc, Dept Hlth Econ Outcomes Res, Foster City, CA USA

[18] Gilead Sci Inc, Dept Clin Dev, Foster City, CA USA

[19] Evidera Inc, Dept Patient Centered Res, Bethesda, MD USA

[20] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Med, San Francisco, CA USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.340

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

392P

引用

页码：S382 / S383

页数：2

共 50 条

[21] ASCENT: A Randomized Phase 3 Study of Sacituzumab Govitecan vs Treatment of Physician's Choice in Patients With Previously Treated Metastatic Triple-Negative Breast Cancer
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (11) : 6 - 9
[22] A quality-adjusted time without symptoms or toxicity (Q-TWIST) analysis comparing lapatinib plus paclitaxel versus paclitaxel alone for first line metastatic breast cancer (MBC) in HER2+patients.
Sherrill, B.
Dileo, A.
Amonkar, M.
Koehler, M.
Arbushites, M.
CANCER RESEARCH, 2009, 69 (02) : 277S - 277S
[23] Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
McDermott, David F.
Shah, Ruchit
Gupte-Singh, Komal
Sabater, Javier
Luo, Linlin
Botteman, Marc
Rao, Sumati
Regan, Meredith M.
Atkins, Michael
QUALITY OF LIFE RESEARCH, 2019, 28 (01) : 109 - 119
[24] Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
David F. McDermott
Ruchit Shah
Komal Gupte-Singh
Javier Sabater
Linlin Luo
Marc Botteman
Sumati Rao
Meredith M. Regan
Michael Atkins
Quality of Life Research, 2019, 28 : 109 - 119
[25] A QUALITY-ADJUSTED TIME WITHOUT SYMPTOMS OR TOXICITY (Q-TWIST) ANALYSIS OF SYSTEMIC THERAPY VERSUS STANDARD OF CARE INTRAVESICAL TREATMENT (BCG) IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
Rivera-Marquez, Genesis
Walter, Beatriz
Dolan, Rebecca
Belfield, Sonia
Valera, Vladimir A.
JOURNAL OF UROLOGY, 2024, 211 (05): : E991 - E992
[26] Assessing the quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) in immuno-oncology (I/O): An application to nivolumab vs. everolimus in previously treated advanced renal cell carcinoma (aRCC).
Shah, Ruchit
Botteman, Marc
Solem, Caitlyn
Luo, Linlin
Doan, Justin
Cella, David
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[27] Quality-adjusted survival of combined nivolumab plus ipilimumab (NIVO plus IPI) or NIVO alone vs IPI among treatment-naive patients (pts) with advanced melanoma (MEL): a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis
Botteman, M.
Shah, R.
Gupte-Singh, K.
Luo, L.
Sabater, J.
Rao, S.
McDermott, D. F.
Atkins, M. B.
Regan, M.
ANNALS OF ONCOLOGY, 2017, 28
[28] Estimated net benefit of avelumab (AVE) plus best supportive care (BSC) vs BSC alone for patients (pts) with advanced urothelial carcinoma (aUC) using a quality-adjusted time without cancer symptoms or toxicity (Q-TWiST) analysis.
Powles, Thomas
Cislo, Paul
Kirker, Melissa
Chang, Jane
Gharibian, Norbek
Thompson, Allison
Costa, Nuno
Grivas, Petros
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[29] Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis to assess the impact of treatment with camrelizumab plus rivoceranib (cam plus rivo) on quality of life vs sorafenib (sora) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study CARES-310
Moon, A.
Raphael, N.
Chan, S. L.
Kaseb, A. O.
Jang, S. H.
Meng, X.
Cheng, A-L.
Qin, S.
Vogel, A.
ANNALS OF ONCOLOGY, 2024, 35 : S663 - S663
[30] Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML
Jorge E. Cortes
Tara L. Lin
Geoffrey L. Uy
Robert J. Ryan
Stefan Faderl
Jeffrey E. Lancet
Journal of Hematology & Oncology, 14

← 1 2 3 4 5 →